The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, announced the first eleven projects in its Powered by CARB-X portfolio March 30. The initial portfolio includes three projects on new classes of antibiotics and four projects on non-traditional products, such as immunotherapy or antibody-drug candidates.
We talked to Executive Director Kevin Outterson about narrowing down applicants from the wide interest and upcoming additions to the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?